Danaher Co. (NYSE:DHR – Free Report) – William Blair lowered their Q1 2025 earnings per share estimates for Danaher in a research report issued on Thursday, January 30th. William Blair analyst M. Larew now forecasts that the conglomerate will post earnings per share of $1.62 for the quarter, down from their prior estimate of $2.00. The consensus estimate for Danaher’s current full-year earnings is $8.15 per share. William Blair also issued estimates for Danaher’s Q3 2025 earnings at $1.94 EPS, FY2025 earnings at $7.62 EPS and Q1 2026 earnings at $1.81 EPS.
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.72% and a net margin of 16.33%. During the same period in the previous year, the company posted $2.09 EPS.
Get Our Latest Stock Report on DHR
Danaher Trading Down 0.2 %
Shares of Danaher stock opened at $222.56 on Monday. The company has a market capitalization of $160.75 billion, a P/E ratio of 42.15, a price-to-earnings-growth ratio of 4.22 and a beta of 0.83. The stock has a fifty day simple moving average of $235.40 and a 200 day simple moving average of $253.08. Danaher has a 12-month low of $221.34 and a 12-month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.
Institutional Trading of Danaher
Hedge funds have recently added to or reduced their stakes in the business. AMF Tjanstepension AB purchased a new stake in Danaher during the 3rd quarter valued at $5,923,000. Czech National Bank increased its holdings in Danaher by 4.2% during the 3rd quarter. Czech National Bank now owns 130,939 shares of the conglomerate’s stock valued at $36,404,000 after purchasing an additional 5,320 shares during the period. GAMMA Investing LLC raised its position in Danaher by 33.5% during the 3rd quarter. GAMMA Investing LLC now owns 4,480 shares of the conglomerate’s stock valued at $1,246,000 after purchasing an additional 1,125 shares during the last quarter. WealthBridge Capital Management LLC grew its position in shares of Danaher by 51.8% in the 3rd quarter. WealthBridge Capital Management LLC now owns 1,465 shares of the conglomerate’s stock worth $407,000 after buying an additional 500 shares during the last quarter. Finally, Diversified Trust Co increased its stake in shares of Danaher by 29.6% during the third quarter. Diversified Trust Co now owns 5,649 shares of the conglomerate’s stock valued at $1,571,000 after buying an additional 1,289 shares during the period. 79.05% of the stock is owned by institutional investors.
Insiders Place Their Bets
In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 11.10% of the company’s stock.
Danaher Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.49%. Danaher’s payout ratio is presently 20.45%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- Options Trading – Understanding Strike Price
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- How Technical Indicators Can Help You Find Oversold Stocks
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
- Ride Out The Recession With These Dividend Kings
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.